Literature DB >> 22614848

Neuromuscular disease: IVIg for neuromuscular disease-effective but expensive.

Richard A Hughes, Michael P Lunn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22614848     DOI： 10.1038/nrneurol.2012.92

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  6 in total

1.  Intravenous immunoglobulin for neuromuscular disease: costs, benefits and reimbursement.

Authors:  John W Griffin; Richard A C Hughes
Journal:  Nat Clin Pract Neurol       Date:  2009-03

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

Review 3.  Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  H S Patwa; V Chaudhry; H Katzberg; A D Rae-Grant; Y T So
Journal:  Neurology       Date:  2012-03-27       Impact factor: 9.910

4.  Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.

Authors:  Gord Blackhouse; Kathryn Gaebel; Feng Xie; Kaitryn Campbell; Nazila Assasi; Jean-Eric Tarride; Daria O'Reilly; Colin Chalk; Mitchell Levine; Ron Goeree
Journal:  Cost Eff Resour Alloc       Date:  2010-06-17

5.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors:  I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

6.  Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome.

Authors:  Jeffrey L Winters; David Brown; Elisabeth Hazard; Ashok Chainani; Chester Andrzejewski
Journal:  BMC Health Serv Res       Date:  2011-05-16       Impact factor: 2.655
  6 in total
  1 in total

Review 1.  New strategies in the management of Guillain-Barré syndrome.

Authors:  Jinting Xiao; Alain R Simard; Fu-Dong Shi; Junwei Hao
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.